Jack T Seki1, Andrea Bozovic2, Roy Lee3, Rita Kwong3, Eshetu G Atenafu4, Anna Xu5, Jin-Hyeun Huh6. 1. , RPh, BSc(Phm), PharmD, is with the Department of Pharmacy, Princess Margaret Cancer Centre, University Health Network, and the Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario. 2. , BSc(Hon), PhD, is with the Department of Laboratory Medicine Program, University Health Network, and the Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario. 3. , RPh, BSc(Phm), is with the Department of Pharmacy, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario. 4. , BSc, MSc, is with the Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario. 5. , BMSc(Hon), is a student in the PharmD program of the Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario. 6. , RPh, BSc(Phm), ACPR, BCPS, is with the Department of Pharmacy, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario.
Abstract
BACKGROUND: The addition of the immunostimulant plerixafor to the current standard-of-care regimens of granulocyte colony-stimulating growth factor with or without chemotherapy has improved clinical results in terms of successful stem cell mobilization and the outcomes of stem cell transplant in various settings. With this medical innovation has come an added financial cost for institutions where stem cell transplants are routinely performed, and there may be a further financial burden when the contents of partial vials of the drug are wasted, given that plerixafor vials (Mozobil, Sanofi-Aventis Canada Inc) are currently deemed suitable only for single use. OBJECTIVE: To determine whether the portion of plerixafor remaining in an opened vial of the Mozobil product after administration of a single dose is chemically stable, by comparison with the original product. METHODS: Stability testing of partial drug contents of an opened vial, stored at room temperature or under refrigeration (4°C), was conducted using liquid chromatography-tandem mass spectrometry analysis. The mean concentration of plerixafor (μmol/L), standard deviation, coefficient of variation, and bias were determined on days 2, 3, 11, 17, 24, and 31. Method validation included determination of precision, sensitivity, recovery, dilution linearity, and carryover. RESULTS: Throughout the 4-week testing period, measured plerixafor concentration in aliquots stored at room temperature and under refrigeration, tested in series over time, appeared similar. The mean residual drug concentration after initial opening was slightly, but not significantly, higher for the sample designated for storage at room temperature than the one designated for refrigerated storage (40.4 versus 39.9 μmol/L; p = 0.37). CONCLUSIONS: Residual plerixafor after initial opening of a vial of the Mozobil product remained chemically stable for at least 2 weeks both at room temperature and under refrigeration. The results of this study provide in vitro evidence to support multiple uses, instead of single use, of vials of this drug in an aseptic, controlled environment.
BACKGROUND: The addition of the immunostimulant plerixafor to the current standard-of-care regimens of granulocyte colony-stimulating growth factor with or without chemotherapy has improved clinical results in terms of successful stem cell mobilization and the outcomes of stem cell transplant in various settings. With this medical innovation has come an added financial cost for institutions where stem cell transplants are routinely performed, and there may be a further financial burden when the contents of partial vials of the drug are wasted, given that plerixafor vials (Mozobil, Sanofi-Aventis Canada Inc) are currently deemed suitable only for single use. OBJECTIVE: To determine whether the portion of plerixafor remaining in an opened vial of the Mozobil product after administration of a single dose is chemically stable, by comparison with the original product. METHODS: Stability testing of partial drug contents of an opened vial, stored at room temperature or under refrigeration (4°C), was conducted using liquid chromatography-tandem mass spectrometry analysis. The mean concentration of plerixafor (μmol/L), standard deviation, coefficient of variation, and bias were determined on days 2, 3, 11, 17, 24, and 31. Method validation included determination of precision, sensitivity, recovery, dilution linearity, and carryover. RESULTS: Throughout the 4-week testing period, measured plerixafor concentration in aliquots stored at room temperature and under refrigeration, tested in series over time, appeared similar. The mean residual drug concentration after initial opening was slightly, but not significantly, higher for the sample designated for storage at room temperature than the one designated for refrigerated storage (40.4 versus 39.9 μmol/L; p = 0.37). CONCLUSIONS: Residual plerixafor after initial opening of a vial of the Mozobil product remained chemically stable for at least 2 weeks both at room temperature and under refrigeration. The results of this study provide in vitro evidence to support multiple uses, instead of single use, of vials of this drug in an aseptic, controlled environment.
Entities:
Keywords:
drug stability; greffe de cellules souches; plerixafor; plérixafor; stabilité des médicaments; stem cell transplant
Authors: Michael S Edwards; Dominic A Solimando; Franklin R Grollman; Janet L Pang; Ashley H Chasick; Charlene M Hightman; Anthony D Johnson; Maxine G Mickens; Lorenzo M Preston Journal: J Oncol Pharm Pract Date: 2013-08-23 Impact factor: 1.809
Authors: Kenneth R Meehan; John M Hill; Linda Patchett; Susan M Webber; Jillian Wu; Pamela Ely; Zbigniew M Szczepiorkowski Journal: Transfusion Date: 2006-04 Impact factor: 3.157
Authors: Nina Worel; Gerhard Fritsch; Hermine Agis; Alexandra Böhm; Georg Engelich; Gerda C Leitner; Klaus Geissler; Karoline Gleixner; Peter Kalhs; Veronika Buxhofer-Ausch; Felix Keil; Gerhard Kopetzky; Viktor Mayr; Werner Rabitsch; Regina Reisner; Konrad Rosskopf; Reinhard Ruckser; Claudia Zoghlami; Niklas Zojer; Hildegard T Greinix Journal: J Clin Apher Date: 2016-08-31 Impact factor: 2.821
Authors: John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Steven M Kymes; Iskra Pusic; Dennis L Lambert; Martin Gregory; Kenneth R Carson; John F DiPersio Journal: Am J Manag Care Date: 2012-01 Impact factor: 2.229